Ursula Creutzig1, Claudia Rössig2, Michael Dworzak3, Jan Stary4, Arend von Stackelberg5, Wilhelm Wössmann6, Martin Zimmermann1, Dirk Reinhardt7. 1. Department of Pediatric Hematology and Oncology Children's Hospital, Hannover Medical School, Hannover, Germany. 2. Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany. 3. Department of Pediatrics, St. Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria. 4. Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. 5. Department of Pediatric Oncology/Hematology, Charité University Medical Center Berlin, Berlin, Germany. 6. Department of Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany. 7. Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
Abstract
BACKGROUND: The risk of early death (ED) by bleeding/leukostasis is high in patients with AML with hyperleukocytosis (>100,000/μl). Within the pediatric AML-BFM (Berlin-Frankfurt-Münster) 98/04 studies, emergency strategies for these children included exchange transfusion (ET) or leukapheresis (LPh). Risk factors for ED and interventions performed were analyzed. PATIENTS: Two hundred thirty-eight of 1,251 (19%) patients with AML presented with hyperleukocytosis; 23 of 1,251 (1.8%) patients died of bleeding/leukostasis. RESULTS: ED due to bleeding/leukostasis was highest at white blood cell (WBC) count >200,000/μl (14.3%). ED rates were even higher (20%) in patients with FAB (French-American-British) M4/M5 and hyperleukocytosis >200,000/μl. Patients with WBC >200,000/μl did slightly better with ET/LPh compared to those without ET/LPh (ED rate 7.5% vs. 21.2%, P = 0.055). Multivariate WBC >200,000/μl was of strongest prognostic significance for ED (P(χ(2) ) <0.0001). CONCLUSION: Our data confirm the high risk of bleeding/leukostasis in patients with hyperleukocytosis. ET/LPh shows a trend toward reduced ED rate due to bleeding/leukostasis and is recommended at WBC >200,000/μl, and in FAB M4/M5 even at lower WBC.
BACKGROUND: The risk of early death (ED) by bleeding/leukostasis is high in patients with AML with hyperleukocytosis (>100,000/μl). Within the pediatric AML-BFM (Berlin-Frankfurt-Münster) 98/04 studies, emergency strategies for these children included exchange transfusion (ET) or leukapheresis (LPh). Risk factors for ED and interventions performed were analyzed. PATIENTS: Two hundred thirty-eight of 1,251 (19%) patients with AML presented with hyperleukocytosis; 23 of 1,251 (1.8%) patients died of bleeding/leukostasis. RESULTS: ED due to bleeding/leukostasis was highest at white blood cell (WBC) count >200,000/μl (14.3%). ED rates were even higher (20%) in patients with FAB (French-American-British) M4/M5 and hyperleukocytosis >200,000/μl. Patients with WBC >200,000/μl did slightly better with ET/LPh compared to those without ET/LPh (ED rate 7.5% vs. 21.2%, P = 0.055). Multivariate WBC >200,000/μl was of strongest prognostic significance for ED (P(χ(2) ) <0.0001). CONCLUSION: Our data confirm the high risk of bleeding/leukostasis in patients with hyperleukocytosis. ET/LPh shows a trend toward reduced ED rate due to bleeding/leukostasis and is recommended at WBC >200,000/μl, and in FAB M4/M5 even at lower WBC.
Authors: Daniel V Runco; Cassandra D Josephson; Sunil S Raikar; Kelly C Goldsmith; Glen Lew; Melinda Pauly; Ross M Fasano Journal: Transfusion Date: 2018-02-04 Impact factor: 3.157
Authors: Rosa Nguyen; Sima Jeha; Yinmei Zhou; Xueyuan Cao; Cheng Cheng; Deepa Bhojwani; Patrick Campbell; Scott C Howard; Jeffrey Rubnitz; Raul C Ribeiro; John T Sandlund; Tanja Gruber; Hiroto Inaba; Ching-Hon Pui; Monika L Metzger Journal: Pediatr Blood Cancer Date: 2016-05-17 Impact factor: 3.167
Authors: Takuto Takahashi; Lucie M Turcotte; Peter M Gordon; Andrew D Johnson; Nathan Rubin; Logan G Spector Journal: J Pediatr Hematol Oncol Date: 2022-03-01 Impact factor: 1.170